Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Thiogenesis Therapeutics Corp (TTI.VN)

Thiogenesis Therapeutics Corp (TTI.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar Newsfile - Mon Jan 5, 8:08AM CST

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome TrialSan Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.610 (-6.15%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis Newsfile - Mon Nov 24, 2025

IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosingSan Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX:...

TTI.VN : 0.610 (-6.15%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis Newsfile - Tue Nov 4, 2025

Trial achieved biological proof-of-concept, dose discovery and biomarker improvementSan Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.610 (-6.15%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Announces Extension to Investor Relations Agreement Newsfile - Fri Oct 3, 2025

San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive...

TTI.VN : 0.610 (-6.15%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update Newsfile - Thu Sep 11, 2025

San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing...

TTI.VN : 0.610 (-6.15%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares Newsfile - Thu Aug 14, 2025

San Diego, California--(Newsfile Corp. - August 14, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news release of August...

TTI.VN : 0.610 (-6.15%)
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares Newsfile - Fri Aug 1, 2025

San Diego, California--(Newsfile Corp. - August 1, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news releases of July...

TTI.VN : 0.610 (-6.15%)
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares Newsfile - Tue Jul 29, 2025

San Diego, California--(Newsfile Corp. - July 29, 2025) - Further to its news release of July 17, 2025, Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce...

TTI.VN : 0.610 (-6.15%)
Thiogenesis Announces Non-Brokered Private Placement of Common Shares Newsfile - Thu Jul 17, 2025

San Diego, California--(Newsfile Corp. - July 17, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement...

TTI.VN : 0.610 (-6.15%)
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU Newsfile - Wed Jun 25, 2025

San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies...

TTI.VN : 0.610 (-6.15%)
TTIPF : 0.5834 (-0.27%)

Barchart Exclusives

Is Google Stock a Buy at New All-Time Highs in January 2026? Barchart - 12 minutes ago
Alphabet’s AI-driven rally looks justified by earnings strength, though the stock now prices in much of Wall Street’s optimism. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot